Our Journey & Honor
Our Experts
Our management
Our Company
Our Vision
Major Milestones

2010
Asieris Pharmaceuticals founded and registered in the China Medical City, Taizhou, Jiangsu Province.
2012
US FDA issued written concurrence of Asieris' proposed phase II clinical protocol to investigate the effects of APL-1202 in non-muscle-invasive bladder cancer patients.
2013 Asieris received the Clinical Trial Approval (CTA) from the China FDA for conducting phase 2 clinical trials in non-muscle invasive bladder cancer patients.
2014
Completed Round A fund raising; initiated the phase 2 trial.
2015 Asieris' APL-1202 received funding support as one of the "National 12th Five-Year Major New Drug Innovation Programs" from the National Health and Family Planning Commission.
2016 Completed APL-1202's China Phase II trial with its therapeutic effects well recognized by both domestic and overseas experts.
2017 APL-1202 pivotal trial initiated.


Our Honors
2012


Asieris was rewarded a grant of the International Science and Technology Cooperation Plan-International Technology Transfer and Joint Research and Development Project by the Science and Technology Department of Jiangsu Province.
2012 Asieris was awarded a grant of the Supporting Science and Technology-Social Development Projects by the Science and Technology Department of Jiangsu Province.
2014
Asieris' APL-1202 awarded as one of the "National 12th Five-Year Major New Drug Innovation Programs" by China's National Health and Family Planning Commission.